How India Exports Salbutamol to the World

In the United States, salbutamol is commonly referred to as albuterol. The FDA has approved numerous Abbreviated New Drug Applications (ANDAs) for albuterol sulfate inhalation products, indicating a competitive generic market. For instance, in 2013, the FDA approved the first generic version of albuterol sulfate inhalation solution, enhancing accessibility for patients.

As of March 2026, there are no active FDA import alerts specifically targeting albuterol sulfate products from India. This absence suggests compliance with FDA standards among Indian manufacturers exporting to the U.S. market. Given the 602 active Indian exporters, this compliance is crucial for maintaining market access and ensuring the continued supply of albuterol products to the United States.

In the European Union, salbutamol-containing products are subject to stringent regulatory oversight. The European Medicines Agency (EMA) has conducted periodic safety assessments, such as the one in November 2023, which led to updates in product information to mitigate risks associated with overuse. (ema.europa.eu) Additionally, in October 2013, the EMA endorsed restrictions on the use of short-acting beta-agonists, including salbutamol, for obstetric indications due to safety concerns. (ema.europa.eu)

The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) aligns with EMA guidelines, ensuring that salbutamol products meet the required safety and efficacy standards. Compliance with EU Good Manufacturing Practice (GMP) requirements is mandatory for manufacturers, emphasizing the importance of quality assurance in the production of salbutamol inhalation products.

Salbutamol is listed in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its critical role in treating respiratory conditions. The inclusion in this list highlights the medication's importance in global health. Manufacturers are expected to adhere to international pharmacopoeia standards, including those set forth by the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), to ensure consistent quality and efficacy.

In India, salbutamol is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines, including salbutamol, to ensure affordability. Manufacturers intending to export salbutamol must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with export regulations and quality standards.

The primary patents for salbutamol have expired, leading to a robust generic market with multiple manufacturers producing the medication. This competitive landscape contributes to the widespread availability and affordability of salbutamol globally.

In November 2023, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) recommended updates to the product information for salbutamol inhalation products to address risks associated with overuse. (ema.europa.eu) This decision underscores the importance of continuous monitoring and updating of safety information to protect public health.

In August 2024, the EMA reported a shortage of salbutamol inhalation products in several EU countries due to increased demand and manufacturing issues. The shortage was expected to continue until early 2026, highlighting the need for robust supply chain management. (ema.europa.eu)

In October 2024, the EMA endorsed restrictions on the use of short-acting beta-agonists, including salbutamol, for obstetric indications due to safety concerns. This decision reflects the agency's commitment to ensuring the safe use of medications across different patient populations. (ema.europa.eu)

In December 2024, the EMA approved a new generic version of salbutamol inhalation solution, increasing competition and potentially reducing costs for patients. This approval demonstrates the agency's support for generic medications as a means to enhance accessibility.

In February 2025, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of salbutamol as a critical medication for respiratory conditions. This inclusion emphasizes the ongoing global recognition of salbutamol's importance in healthcare.

These developments highlight the dynamic nature of the regulatory landscape for salbutamol, emphasizing the need for manufacturers and exporters to stay informed and compliant with evolving standards and requirements.

India's pharmaceutical industry heavily relies on China for Key Starting Materials (KSMs) essential in Active Pharmaceutical Ingredient (API) production. Approximately 60–70% of these materials are imported from China, creating a dependency that poses risks to the supply chain. This reliance makes the production of APIs like Salbutamol vulnerable to disruptions in Chinese supply chains, whether due to geopolitical tensions, trade restrictions, or other unforeseen events.

The COVID-19 pandemic highlighted the fragility of this dependency, as lockdowns and export restrictions in China led to significant shortages of essential pharmaceuticals globally. Although efforts have been made to diversify sourcing and enhance domestic production, the Indian pharmaceutical sector remains susceptible to similar disruptions, which could affect the availability and pricing of Salbutamol.

The export market for Salbutamol from India is highly concentrated, with the top five exporters accounting for 79.6% of total exports. CIPLA LIMITED alone holds a 67.4% share, amounting to $100.3 million USD. This concentration poses a significant single-source risk; any operational issues, regulatory challenges, or disruptions within these key companies could severely impact the global supply of Salbutamol.

To mitigate such risks, the Indian government has introduced the Production Linked Incentive (PLI) scheme, aiming to boost domestic manufacturing of critical APIs and reduce dependency on imports. However, the effectiveness of this initiative in diversifying the supplier base and enhancing supply chain resilience for Salbutamol remains to be fully realized.

Recent geopolitical tensions have led to significant disruptions in key maritime routes. The closure of the Strait of Hormuz in March 2026, following military escalations involving the United States and Iran, has severely impacted global shipping lanes. This strait is a vital conduit for global trade, and its closure has led to increased shipping costs and delays. Such disruptions can affect the timely delivery of pharmaceuticals like Salbutamol, leading to potential shortages in destination markets.

Additionally, the Red Sea has experienced heightened security threats, prompting major shipping companies to suspend transits through this route. These disruptions necessitate rerouting shipments, resulting in longer transit times and increased costs. The cumulative effect of these geopolitical events underscores the vulnerability of the Salbutamol supply chain to external shocks.

• Diversify API Sourcing: Encourage the development of alternative sources for KSMs and APIs to reduce dependency on a single country, thereby enhancing supply chain resilience.

• Expand Supplier Base: Support the growth of additional manufacturers to decrease reliance on a few key exporters, mitigating single-source risks.

• Enhance Domestic Production: Strengthen initiatives like the PLI scheme to boost domestic manufacturing capabilities for critical pharmaceuticals, reducing import dependency.

• Develop Contingency Plans: Establish robust contingency strategies to address potential shipping disruptions, including identifying alternative routes and transportation methods.

• Monitor Geopolitical Developments: Implement proactive monitoring of geopolitical events that could impact supply chains, enabling timely responses to emerging threats.

Given the current landscape, the supply chain risk level for Salbutamol exported from India is assessed as:

RISK_LEVEL: HIGH